HUP0201224A3 - Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma - Google Patents

Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma

Info

Publication number
HUP0201224A3
HUP0201224A3 HU0201224A HUP0201224A HUP0201224A3 HU P0201224 A3 HUP0201224 A3 HU P0201224A3 HU 0201224 A HU0201224 A HU 0201224A HU P0201224 A HUP0201224 A HU P0201224A HU P0201224 A3 HUP0201224 A3 HU P0201224A3
Authority
HU
Hungary
Prior art keywords
gliobastoma
treating
release
anticancer agent
biodegradable microspheres
Prior art date
Application number
HU0201224A
Other languages
English (en)
Original Assignee
Ethypharm Lab Prod Ethiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Lab Prod Ethiques filed Critical Ethypharm Lab Prod Ethiques
Publication of HUP0201224A2 publication Critical patent/HUP0201224A2/hu
Publication of HUP0201224A3 publication Critical patent/HUP0201224A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
HU0201224A 1999-05-17 2000-05-17 Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma HUP0201224A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9906207A FR2793684B1 (fr) 1999-05-17 1999-05-17 Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant

Publications (2)

Publication Number Publication Date
HUP0201224A2 HUP0201224A2 (hu) 2002-11-28
HUP0201224A3 true HUP0201224A3 (en) 2004-05-28

Family

ID=9545636

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201224A HUP0201224A3 (en) 1999-05-17 2000-05-17 Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma

Country Status (30)

Country Link
US (2) US6803052B2 (hu)
EP (2) EP1228755A1 (hu)
JP (1) JP5230045B2 (hu)
KR (1) KR100649948B1 (hu)
CN (1) CN1210020C (hu)
AR (1) AR024008A1 (hu)
AT (1) ATE228353T1 (hu)
AU (1) AU775320B2 (hu)
BG (1) BG64936B1 (hu)
BR (1) BR0010648A (hu)
CA (1) CA2388656C (hu)
CZ (1) CZ20014137A3 (hu)
DE (1) DE60000842T2 (hu)
DK (1) DK1053746T3 (hu)
EA (1) EA004943B1 (hu)
ES (1) ES2185544T3 (hu)
FR (1) FR2793684B1 (hu)
HK (1) HK1047044B (hu)
HU (1) HUP0201224A3 (hu)
IL (2) IL146467A0 (hu)
MX (1) MXPA01011919A (hu)
NO (1) NO331686B1 (hu)
NZ (1) NZ515515A (hu)
PL (1) PL201614B1 (hu)
PT (1) PT1053746E (hu)
SI (1) SI1053746T1 (hu)
SK (1) SK16342001A3 (hu)
TW (1) TWI229608B (hu)
WO (1) WO2000069413A1 (hu)
ZA (1) ZA200109415B (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7096864B1 (en) 1999-08-05 2006-08-29 Map Medizin-Technologie Gmbh Device for supplying respiratory gas
AUPR098300A0 (en) 2000-10-25 2000-11-16 Sirtex Medical Limited Polymer based radionuclide containing microspheres
JP2002154963A (ja) * 2000-11-14 2002-05-28 Yakult Honsha Co Ltd 徐放性抗腫瘍剤
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
CN1520313A (zh) * 2001-05-23 2004-08-11 ������ҩ��ʽ���� 一种加速骨折愈合的组合物
CN1537018A (zh) * 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
CA2452412C (en) 2001-06-29 2011-05-24 Medgraft Microtech, Inc. Biodegradable injectable implants and related methods of manufacture and use
UA77999C2 (en) * 2001-12-10 2007-02-15 Thymosin-alpha 1 for treatment of malignant glioblastoma
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
US8986737B2 (en) 2002-09-05 2015-03-24 Wm. Marsh Rice University Antibiotic microspheres for treatment and prevention of osteomyelitis and enhancement of bone regrowth
CA3081288C (en) 2003-06-20 2022-10-18 ResMed Pty Ltd Breathable gas apparatus with humidifier
WO2005023293A1 (en) * 2003-09-09 2005-03-17 Pohang University Of Science And Technology Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
CA2560261A1 (en) * 2004-03-18 2005-09-29 St. Luke's Hospital Method for the delivery of sustained release agents
US8088413B2 (en) * 2004-04-16 2012-01-03 Nuvue Therapeutics, Inc. Methods for improved cryo-chemotherapy tissue ablation
JP4929159B2 (ja) 2004-04-16 2012-05-09 ヌーヴ セラピュティクス、インコーポレイテッド 画像誘導組織切除を改善するための装置
JP5221134B2 (ja) 2004-09-07 2013-06-26 バイオコンパティブルズ ユーケー リミテッド 塞栓剤からの薬物送達
US8702580B2 (en) * 2004-10-06 2014-04-22 Brainlab Ag Method and device for assisting in a tissue treatment
CN100386115C (zh) * 2004-10-14 2008-05-07 孔庆忠 一种抗癌药物组合物
CN1299685C (zh) * 2005-01-26 2007-02-14 上海大学 氟尿嘧啶载药微球及其制备方法
CN100340297C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 抗癌体内植入剂
CN1923281B (zh) * 2005-08-30 2010-05-05 孔庆忠 一种含植物生物碱的抗癌缓释注射剂
CN100464785C (zh) * 2005-08-30 2009-03-04 孔庆忠 一种抗癌药物缓释注射剂及其应用
CN1923282B (zh) * 2005-08-30 2010-05-05 孔庆忠 一种含激素类药物的抗癌缓释注射剂
CN1923173B (zh) * 2006-02-24 2010-05-19 济南康泉医药科技有限公司 一种同载抗癌抗生素及其增效剂的抗癌药物缓释剂
WO2007105218A2 (en) * 2006-03-14 2007-09-20 Yeda Research And Development Co. Ltd. Composition and method for brain tumor therapy
CN100464736C (zh) * 2006-03-17 2009-03-04 山东蓝金生物工程有限公司 同载抗代谢药物及其增效剂的抗癌缓释注射剂
EP1985286A1 (en) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microspheres for treatment of brain tumours
HUE052136T2 (hu) 2011-12-13 2021-04-28 Engeneic Molecular Delivery Pty Ltd Bakteriális eredetû intakt minisejtek terápiás szerek agydaganatokba történõ bejuttatására
US10342769B2 (en) * 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
EP3373907A4 (en) * 2015-11-11 2019-12-18 Qrono, Inc. EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
CN111050750A (zh) 2017-08-24 2020-04-21 诺沃挪第克公司 Glp-1组合物及其用途
EP4106727A1 (en) 2020-02-18 2022-12-28 Novo Nordisk A/S Pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
WO1998016242A1 (en) * 1996-10-16 1998-04-23 Regeneron Pharmaceuticals, Inc. Method of enhancing the delivery of growth factors
WO1998043977A1 (fr) * 1997-03-31 1998-10-08 Toray Industries, Inc. Derives de quinolinomorphinane et leur usage medical
CA2306228A1 (en) * 1997-10-14 1999-04-22 Cambridge Neuroscience, Inc. Therapeutic methods comprising use of a neuregulin

Also Published As

Publication number Publication date
IL146467A0 (en) 2002-07-25
US6803052B2 (en) 2004-10-12
SK16342001A3 (sk) 2002-08-06
KR20020000178A (ko) 2002-01-04
US7041241B2 (en) 2006-05-09
DK1053746T3 (da) 2003-03-31
JP5230045B2 (ja) 2013-07-10
MXPA01011919A (es) 2002-05-06
CZ20014137A3 (cs) 2002-06-12
TWI229608B (en) 2005-03-21
PT1053746E (pt) 2003-04-30
AU775320B2 (en) 2004-07-29
HK1047044B (zh) 2005-12-23
HK1047044A1 (en) 2003-02-07
IL146467A (en) 2006-06-11
AU4764100A (en) 2000-12-05
JP2002544219A (ja) 2002-12-24
ES2185544T3 (es) 2003-05-01
BG106106A (en) 2002-05-31
PL201614B1 (pl) 2009-04-30
NO20015501D0 (no) 2001-11-09
US20030175356A1 (en) 2003-09-18
AR024008A1 (es) 2002-09-04
EA200101206A1 (ru) 2002-04-25
BR0010648A (pt) 2002-02-19
NO331686B1 (no) 2012-02-20
DE60000842T2 (de) 2003-08-28
EP1228755A1 (fr) 2002-08-07
CA2388656A1 (fr) 2000-11-23
NZ515515A (en) 2004-02-27
ZA200109415B (en) 2003-01-29
EA004943B1 (ru) 2004-10-28
BG64936B1 (bg) 2006-10-31
FR2793684A1 (fr) 2000-11-24
US20020051749A1 (en) 2002-05-02
EP1053746B1 (fr) 2002-11-27
PL352372A1 (en) 2003-08-25
EP1053746A1 (fr) 2000-11-22
DE60000842D1 (de) 2003-01-09
ATE228353T1 (de) 2002-12-15
CN1210020C (zh) 2005-07-13
HUP0201224A2 (hu) 2002-11-28
KR100649948B1 (ko) 2006-11-24
CA2388656C (fr) 2011-04-26
FR2793684B1 (fr) 2001-08-10
CN1356892A (zh) 2002-07-03
SI1053746T1 (en) 2003-04-30
NO20015501L (no) 2002-01-09
WO2000069413A1 (fr) 2000-11-23

Similar Documents

Publication Publication Date Title
IL146467A0 (en) Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma
EP1205459A4 (en) GAS-CREATING COMPOSITION FOR BELTS
HUP0202049A3 (en) Indole derivatives and their use for the treatment of osteoporosis amongst other applications
EP1189597A4 (en) COMPOSITIONS USING AN OIL CORE FOR DELAYED RELEASE HYDROPHOLE MEDICAMENTS
EP1163852A4 (en) MASKING AGENT
EP1225971A4 (en) CONTROLLED RELEASE OF SUBSTANCES
SI1274427T1 (sl) Formulacija substituiranih benzimidazolov
AU6510400A (en) Slow release microspheres
HUP0103807A3 (en) Device for dispersal of fluidized powder
IL144603A0 (en) Controlled release formulation for treating copd
SG92610A1 (en) The use of des-aspartate-angiotensin i as an agent for the treatment and prevention of neointima formation, restenosis, and arteriosclerosis
HUP0200288A3 (en) Use of pde4 for treating copd
GB2356831B (en) Release agent delivery system and method for printer devices
EP1189610A4 (en) METHOD AND MARKERS FOR PROGNOSING THE EFFECTIVENESS OF CANCER AGENTS
GB9904485D0 (en) Method for protecting and/or controlled release of active ingredient
EP1086921A4 (en) LIFT SAFETY DEVICE
GB2371748B (en) HMG-COA reductase inhibitor extended release formulation
GB9911546D0 (en) Release of poorly soluble agents
GB0124327D0 (en) Spring loaded hydraulic release brake
EP1218025A4 (en) USE OF MULLER CHANNEL INHIBITION SUBSTANCE FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS CHARACTERIZED BY EXCESS ANDROGENES
ZA200002041B (en) Agent for enhancing cerebral aceylcholine release.
GB9908962D0 (en) Calcified microspheres
TW449230U (en) Improved through-hole pad of PCB
TW391404U (en) Brake device of stroller
TW408799U (en) Noise inhibiting mechanism of circuit breaking brake device

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees